Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | EDNRB | P24530 | 1/20 | 0.42 |
| ▸ | EDNRA | P25101 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5364639 | 0.84 | TSHR (0.53) | LMNATDP1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL18531914 | 0.78 | LMNA (0.41) | LMNATDP1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL9052757 | 0.78 | LMNA (0.41) | LMNATDP1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL2844487 | 0.77 | KDM4E (0.50) | LMNATDP1KDM4EALDH1A1ALOX15 | |
| SCHEMBL10613852 | 0.76 | POLB (0.48) | SMN1; SMN2POLBCYP1A2 | |
| SCHEMBL27716808 | 0.75 | CYP1A2 (0.46) | LMNATDP1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL8986465 | 0.75 | PKM (0.41) | LMNATDP1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL3444212 | 0.75 | PTGS1 (0.53) | LMNATDP1KDM4EALDH1A1POLB | |
| SCHEMBL7012356 | 0.75 | LMNA (0.56) | LMNATDP1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL6333728 | 0.74 | L3MBTL1 (0.48) | LMNATDP1SMN1; SMN2CYP1A2EDNRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100418955-C | Novel Benzo-fused heterocycles | ACTELION PHARMOUEUTICALS LTD (CH) | 2008-09-17 | — | — | CN | disclosed |
| US-7238685-B2 | Benzo-fused heterocycles as endothelin antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-07-03 | — | — | US | disclosed |
| US-20050124605-A1 | Novel benzo-fused heterocycles as endothelin antagonisits | ACTELION PHARMACEUTICALS LTD. | 2005-06-09 | — | — | US | disclosed |
| WO-2003013545-A1 | NOVEL BENZO-FUSED HETEROCYCLES AS ENDOTHELIN ANTAGONISITS | ACTELION PHARMACEUTICALS LTD (CH) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124605-A1 | Novel benzo-fused heterocycles as endothelin antagonisits | EDNRA, EDNRB, ECE1 | LMNA 983/4885TDP1 2012/4885KDM4E 887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.